obesity

In a move to demystify the conversation around obesity and weight management medications, Oprah Winfrey has taken to the airwaves with a prime-time special that delves into the stigma associated with weight loss drugs like Ozempic and Wegovy. What Happened: Winfrey dedicated a prime-time special to...

The Centers for Medicare and Medicaid Services (CMS) is considering the inclusion of Novo Nordisk’s (NYSE:NVO) obesity drug Wegovy in its coverage for heart disease patients with obesity. What Happened: The CMS is reviewing the FDA's action to expand the use of Wegovy to reduce the risk of...

Ozempic maker Novo Nordisk (NYSE:NVO), a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in response to the rising obesity rates in the country. What Happened: Despite Japan’s reputation for being health-conscious, the country has seen a...

WW International Inc. (NASDAQ:WW) reported its fourth-quarter financial results after the bell Wednesday. The company also announced Oprah Winfrey decided not to stand for re-election to its board of directors. The Details: WW International reported quarterly adjusted losses per share of $1.11....

How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic. Those with obesity drugs already on the market...

Danish pharma giant Novo Nordisk A/S (NYSE:NVO) reported a strong increase in first-half sales and profits and also hiked its guidance for the full year for the second time this year. What Happened: Novo Nordisk said its net sales for the first half of the year climbed 29% year-over-year to 107.67...

Two new drugs, Orforglipron and Retatrutide, are set to redefine the obesity treatment landscape with their potential affordability and unprecedented efficacy, Scientific American reports. Potential Game Changers: Orforglipron, one of the two drugs, is anticipated to be easier to use, produce, and...

Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd. (NASDAQ: SPRC) shared the initial positive pre-clinical results of Clearmind’s novel psychedelic molecule, MEAI, for the treatment of obesity and potential treatment of metabolic...

Western Australia has proposed banning fast-food giants, including Yum! Brands Inc.'s (NYSE:YUM) KFC and McDonald’s Corp. (NYSE:MCD), from near schools and slashing their opening hours as it looks to tackle the growing obesity problems in the region. What Happened: A report released by the...

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk's startup Neuralink brain chip could help treat morbid obesity; that's what Musk believes. Echoing Musk's statement, scientists say it's not an impossibility.  Responding to a Twitter post on the same line, Musk said that it is...

The FDA has cleared Altimmune Inc's (NASDAQ: ALT) Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity.  Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist under development to treat obesity and nonalcoholic...

Novo Nordisk A/S (NYSE: NVO) said that a contract manufacturer filling syringes for pens to inject Wegovy (semaglutide) had temporarily halted deliveries and manufacturing after issues relating to good manufacturing practices. Consequently, fewer new patients will start treatment...

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the authorization of Novo Nordisk A/S's (NYSE: NVO) Wegovy for chronic weight management in adults with obesity. Wegovy is a once-weekly semaglutide 2.4 mg injection. The...

H.C. Wainwright said that Altimmune Inc (NASDAQ: ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients.  However, shares dropped, which he sees primarily because one patient experienced elevated ALT levels that...

Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. At 12 weeks, those who received pemvidutide achieved mean weight losses of 4.9%, 10.3%, and 9.0% at the...